ID   PK3CB_HUMAN             Reviewed;        1070 AA.
AC   P42338; D3DNF0; Q24JU2;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   10-MAY-2017, entry version 167.
DE   RecName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform;
DE            Short=PI3-kinase subunit beta;
DE            Short=PI3K-beta;
DE            Short=PI3Kbeta;
DE            Short=PtdIns-3-kinase subunit beta;
DE            EC=2.7.1.153;
DE   AltName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit beta;
DE            Short=PtdIns-3-kinase subunit p110-beta;
DE            Short=p110beta;
GN   Name=PIK3CB; Synonyms=PIK3C1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8246984; DOI=10.1128/MCB.13.12.7677;
RA   Hu P., Mondino A., Skolnik E.Y., Schlessinger J.;
RT   "Cloning of a novel, ubiquitously expressed human phosphatidylinositol
RT   3-kinase and identification of its binding site on p85.";
RL   Mol. Cell. Biol. 13:7677-7688(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=11016459; DOI=10.2337/diabetes.49.10.1740;
RA   Kossila M., Sinkovic M., Karkkainen P., Laukkanen M.O., Miettinen R.,
RA   Rissanen J., Kekalainen P., Kuusisto J., Yla-Herttuala S., Laakso M.;
RT   "Gene encoding the catalytic subunit p110beta of human
RT   phosphatidylinositol 3-kinase: cloning, genomic structure, and
RT   screening for variants in patients with type 2 diabetes.";
RL   Diabetes 49:1740-1743(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PHOSPHORYLATION AT SER-1070.
RX   PubMed=12502714; DOI=10.1074/jbc.M210351200;
RA   Czupalla C., Culo M., Muller E.C., Brock C., Reusch H.P., Spicher K.,
RA   Krause E., Nurnberg B.;
RT   "Identification and characterization of the autophosphorylation sites
RT   of phosphoinositide 3-kinase isoforms beta and gamma.";
RL   J. Biol. Chem. 278:11536-11545(2003).
RN   [6]
RP   FUNCTION, AND MUTAGENESIS OF LYS-805.
RX   PubMed=18594509; DOI=10.1038/nature07091;
RA   Jia S., Liu Z., Zhang S., Liu P., Zhang L., Lee S.H., Zhang J.,
RA   Signoretti S., Loda M., Roberts T.M., Zhao J.J.;
RT   "Essential roles of PI(3)K-p110beta in cell growth, metabolism and
RT   tumorigenesis.";
RL   Nature 454:776-779(2008).
RN   [7]
RP   FUNCTION IN ONCOGENIC SIGNALING.
RX   PubMed=18755892; DOI=10.1073/pnas.0802655105;
RA   Wee S., Wiederschain D., Maira S.-M., Loo A., Miller C.,
RA   deBeaumont R., Stegmeier F., Yao Y.-M., Lengauer C.;
RT   "PTEN-deficient cancers depend on PIK3CB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:13057-13062(2008).
RN   [8]
RP   IDENTIFICATION IN A COMPLEX WITH PIK3R1 AND PTEN.
RX   PubMed=19635806; DOI=10.1128/MCB.01649-08;
RA   Rabinovsky R., Pochanard P., McNear C., Brachmann S.M.,
RA   Duke-Cohan J.S., Garraway L.A., Sellers W.R.;
RT   "p85 Associates with unphosphorylated PTEN and the PTEN-associated
RT   complex.";
RL   Mol. Cell. Biol. 29:5377-5388(2009).
RN   [9]
RP   FUNCTION, AND MUTAGENESIS OF LYS-342.
RX   PubMed=21030680; DOI=10.1073/pnas.1008739107;
RA   Dbouk H.A., Pang H., Fiser A., Backer J.M.;
RT   "A biochemical mechanism for the oncogenic potential of the p110beta
RT   catalytic subunit of phosphoinositide 3-kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:19897-19902(2010).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   FUNCTION, INTERACTION WITH PIK3R2, SUBCELLULAR LOCATION, AND MOTIF
RP   NUCLEAR LOCALIZATION SIGNAL.
RX   PubMed=21383062; DOI=10.1128/MCB.01313-10;
RA   Kumar A., Redondo-Munoz J., Perez-Garcia V., Cortes I., Chagoyen M.,
RA   Carrera A.C.;
RT   "Nuclear but not cytosolic phosphoinositide 3-kinase beta has an
RT   essential function in cell survival.";
RL   Mol. Cell. Biol. 31:2122-2133(2011).
RN   [12]
RP   REVIEW ON FUNCTION.
RX   PubMed=21321382;
RA   Dbouk H.A., Backer J.M.;
RT   "A beta version of life: p110beta takes center stage.";
RL   Oncotarget 1:729-733(2010).
RN   [13]
RP   REVIEW ON FUNCTION.
RX   PubMed=21035500; DOI=10.1016/j.advenzreg.2010.09.011;
RA   Gratacap M.-P., Guillermet-Guibert J., Martin V., Chicanne G.,
RA   Tronchere H., Gaits-Iacovoni F., Payrastre B.;
RT   "Regulation and roles of PI3Kbeta, a major actor in platelet signaling
RT   and functions.";
RL   Adv. Enzyme Regul. 51:106-116(2011).
CC   -!- FUNCTION: Phosphoinositide-3-kinase (PI3K) that phosphorylates
CC       PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-
CC       phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-
CC       bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate
CC       (PIP3). PIP3 plays a key role by recruiting PH domain-containing
CC       proteins to the membrane, including AKT1 and PDPK1, activating
CC       signaling cascades involved in cell growth, survival,
CC       proliferation, motility and morphology. Involved in the activation
CC       of AKT1 upon stimulation by G-protein coupled receptors (GPCRs)
CC       ligands such as CXCL12, sphingosine 1-phosphate, and
CC       lysophosphatidic acid. May also act downstream receptor tyrosine
CC       kinases. Required in different signaling pathways for stable
CC       platelet adhesion and aggregation. Plays a role in platelet
CC       activation signaling triggered by GPCRs, alpha-IIb/beta-3
CC       integrins (ITGA2B/ ITGB3) and ITAM (immunoreceptor tyrosine-based
CC       activation motif)-bearing receptors such as GP6. Regulates the
CC       strength of adhesion of ITGA2B/ ITGB3 activated receptors
CC       necessary for the cellular transmission of contractile forces.
CC       Required for platelet aggregation induced by F2 (thrombin) and
CC       thromboxane A2 (TXA2). Has a role in cell survival. May have a
CC       role in cell migration. Involved in the early stage of
CC       autophagosome formation. Modulates the intracellular level of
CC       PtdIns3P (Phosphatidylinositol 3-phosphate) and activates PIK3C3
CC       kinase activity. May act as a scaffold, independently of its lipid
CC       kinase activity to positively regulate autophagy. May have a role
CC       in insulin signaling as scaffolding protein in which the lipid
CC       kinase activity is not required. May have a kinase-independent
CC       function in regulating cell proliferation and in clathrin-mediated
CC       endocytosis. Mediator of oncogenic signal in cell lines lacking
CC       PTEN. The lipid kinase activity is necessary for its role in
CC       oncogenic transformation. Required for the growth of ERBB2 and RAS
CC       driven tumors. {ECO:0000269|PubMed:18594509,
CC       ECO:0000269|PubMed:18755892, ECO:0000269|PubMed:21030680,
CC       ECO:0000269|PubMed:21383062}.
CC   -!- CATALYTIC ACTIVITY: ATP + 1-phosphatidyl-1D-myo-inositol 4,5-
CC       bisphosphate = ADP + 1-phosphatidyl-1D-myo-inositol 3,4,5-
CC       trisphosphate.
CC   -!- PATHWAY: Phospholipid metabolism; phosphatidylinositol phosphate
CC       biosynthesis.
CC   -!- SUBUNIT: Heterodimer of a catalytic subunit PIK3CB and a p85
CC       regulatory subunit (PIK3R1, PIK3R2 or PIK3R3). Interaction with
CC       PIK3R2 is required for nuclear localization and nuclear export.
CC       Part of a complex with PIK3R1 and PTEN. Binding to PTEN may
CC       antagonize the lipid kinase activity under normal growth
CC       conditions. Part of a complex involved in autophagosome formation
CC       composed of PIK3C3 and PIK3R4 (By similarity). Interacts with
CC       BECN1, ATG14 and RAB5A (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P08631:HCK; NbExp=2; IntAct=EBI-2609540, EBI-346340;
CC       P27986:PIK3R1; NbExp=2; IntAct=EBI-2609540, EBI-79464;
CC       P27986-2:PIK3R1; NbExp=3; IntAct=EBI-2609540, EBI-9090282;
CC       O00459:PIK3R2; NbExp=3; IntAct=EBI-2609540, EBI-346930;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:21383062}.
CC       Nucleus {ECO:0000269|PubMed:21383062}. Note=Interaction with
CC       PIK3R2 is required for nuclear localization and export.
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously.
CC   -!- DOMAIN: The inhibitory interactions with PIK3R1 are mediated by
CC       the PI3K-ABD domain and the C2 PI3K-type domain with the iSH2
CC       (inter-SH2) region of PIK3R1; the C2 PI3K-type domain, the PI3K
CC       helical domain, and the PI3K/PI4K kinase domain with the nSH2 (N-
CC       terminal SH2) region of PIK3R1; and the PI3K/PI4K kinase domain
CC       with the cSH2 (C-terminal SH2) region of PIK3R1. The inhibitory
CC       interaction between the PI3K-ABD domain and the C2 PI3K-type
CC       domain with the iSH2 (inter-SH2) region of PIK3R1 is weak. The
CC       nuclear localization signal (NLS) is required for its function in
CC       cell survival.
CC   -!- PTM: Phosphorylation at Ser-1070 down-regulates lipid kinase
CC       activity. {ECO:0000269|PubMed:12502714}.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00877, ECO:0000255|PROSITE-
CC       ProRule:PRU00879, ECO:0000255|PROSITE-ProRule:PRU00880}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S67334; AAB29081.1; -; mRNA.
DR   EMBL; AJ297549; CAC21449.1; -; Genomic_DNA.
DR   EMBL; AJ297550; CAC21449.1; JOINED; Genomic_DNA.
DR   EMBL; AJ297551; CAC21449.1; JOINED; Genomic_DNA.
DR   EMBL; AJ297552; CAC21449.1; JOINED; Genomic_DNA.
DR   EMBL; AJ297553; CAC21449.1; JOINED; Genomic_DNA.
DR   EMBL; AJ297554; CAC21449.1; JOINED; Genomic_DNA.
DR   EMBL; AJ297555; CAC21449.1; JOINED; Genomic_DNA.
DR   EMBL; AJ297556; CAC21449.1; JOINED; Genomic_DNA.
DR   EMBL; AJ297557; CAC21449.1; JOINED; Genomic_DNA.
DR   EMBL; AJ297558; CAC21449.1; JOINED; Genomic_DNA.
DR   EMBL; AJ297559; CAC21449.1; JOINED; Genomic_DNA.
DR   EMBL; AJ297560; CAC21449.1; JOINED; Genomic_DNA.
DR   EMBL; CH471052; EAW79053.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79055.1; -; Genomic_DNA.
DR   EMBL; BC114432; AAI14433.1; -; mRNA.
DR   CCDS; CCDS3104.1; -.
DR   PIR; A54600; A54600.
DR   RefSeq; NP_006210.1; NM_006219.2.
DR   RefSeq; XP_005247587.1; XM_005247530.2.
DR   RefSeq; XP_006713722.1; XM_006713659.3.
DR   RefSeq; XP_011511197.1; XM_011512895.2.
DR   RefSeq; XP_016862108.1; XM_017006619.1.
DR   UniGene; Hs.239818; -.
DR   ProteinModelPortal; P42338; -.
DR   SMR; P42338; -.
DR   BioGrid; 111309; 39.
DR   DIP; DIP-44775N; -.
DR   IntAct; P42338; 18.
DR   MINT; MINT-1505441; -.
DR   STRING; 9606.ENSP00000289153; -.
DR   BindingDB; P42338; -.
DR   ChEMBL; CHEMBL3145; -.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB05241; XL765.
DR   GuidetoPHARMACOLOGY; 2154; -.
DR   iPTMnet; P42338; -.
DR   PhosphoSitePlus; P42338; -.
DR   BioMuta; PIK3CB; -.
DR   DMDM; 1171955; -.
DR   EPD; P42338; -.
DR   MaxQB; P42338; -.
DR   PaxDb; P42338; -.
DR   PeptideAtlas; P42338; -.
DR   PRIDE; P42338; -.
DR   DNASU; 5291; -.
DR   Ensembl; ENST00000289153; ENSP00000289153; ENSG00000051382.
DR   Ensembl; ENST00000477593; ENSP00000418143; ENSG00000051382.
DR   GeneID; 5291; -.
DR   KEGG; hsa:5291; -.
DR   UCSC; uc011bmq.4; human.
DR   CTD; 5291; -.
DR   DisGeNET; 5291; -.
DR   GeneCards; PIK3CB; -.
DR   HGNC; HGNC:8976; PIK3CB.
DR   HPA; CAB031938; -.
DR   HPA; HPA064207; -.
DR   MIM; 602925; gene.
DR   neXtProt; NX_P42338; -.
DR   OpenTargets; ENSG00000051382; -.
DR   PharmGKB; PA33309; -.
DR   eggNOG; KOG0904; Eukaryota.
DR   eggNOG; COG5032; LUCA.
DR   GeneTree; ENSGT00760000119110; -.
DR   HOGENOM; HOG000252911; -.
DR   HOVERGEN; HBG052721; -.
DR   InParanoid; P42338; -.
DR   KO; K00922; -.
DR   OMA; CLKQNAY; -.
DR   OrthoDB; EOG091G027R; -.
DR   PhylomeDB; P42338; -.
DR   TreeFam; TF102031; -.
DR   BioCyc; MetaCyc:HS00644-MONOMER; -.
DR   BRENDA; 2.7.1.137; 2681.
DR   BRENDA; 2.7.1.153; 2681.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-186763; Downstream signal transduction.
DR   Reactome; R-HSA-198203; PI3K/AKT activation.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-HSA-210993; Tie2 Signaling.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization.
DR   Reactome; R-HSA-373753; Nephrin interactions.
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-512988; Interleukin-3, 5 and GM-CSF signaling.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   Reactome; R-HSA-912526; Interleukin receptor SHC signaling.
DR   Reactome; R-HSA-912631; Regulation of signaling by CBL.
DR   SignaLink; P42338; -.
DR   SIGNOR; P42338; -.
DR   UniPathway; UPA00220; -.
DR   GeneWiki; PIK3CB; -.
DR   GenomeRNAi; 5291; -.
DR   PRO; PR:P42338; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000051382; -.
DR   CleanEx; HS_PIK3CB; -.
DR   ExpressionAtlas; P42338; baseline and differential.
DR   Genevisible; P42338; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030496; C:midbody; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IBA:GO_Central.
DR   GO; GO:0035005; F:1-phosphatidylinositol-4-phosphate 3-kinase activity; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IEA:Ensembl.
DR   GO; GO:0016301; F:kinase activity; IDA:MGI.
DR   GO; GO:0035004; F:phosphatidylinositol 3-kinase activity; TAS:UniProtKB.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; IBA:GO_Central.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:ProtInc.
DR   GO; GO:0060055; P:angiogenesis involved in wound healing; IEA:Ensembl.
DR   GO; GO:0006914; P:autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0016477; P:cell migration; TAS:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0006935; P:chemotaxis; TAS:ProtInc.
DR   GO; GO:0040016; P:embryonic cleavage; IEA:Ensembl.
DR   GO; GO:0001935; P:endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0038096; P:Fc-gamma receptor signaling pathway involved in phagocytosis; TAS:Reactome.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0007156; P:homophilic cell adhesion via plasma membrane adhesion molecules; IEA:Ensembl.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IMP:CAFA.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0016310; P:phosphorylation; IDA:MGI.
DR   GO; GO:0030168; P:platelet activation; TAS:UniProtKB.
DR   GO; GO:0070527; P:platelet aggregation; TAS:UniProtKB.
DR   GO; GO:0010508; P:positive regulation of autophagy; TAS:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:MGI.
DR   GO; GO:0033031; P:positive regulation of neutrophil apoptotic process; IMP:CAFA.
DR   GO; GO:0001952; P:regulation of cell-matrix adhesion; IMP:MGI.
DR   GO; GO:2000369; P:regulation of clathrin-dependent endocytosis; TAS:UniProtKB.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; NAS:ProtInc.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; TAS:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   Gene3D; 1.10.1070.11; -; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR003113; PI3K_adapt-bd_dom.
DR   InterPro; IPR002420; PI3K_C2_dom.
DR   InterPro; IPR000341; PI3K_Ras-bd_dom.
DR   InterPro; IPR015433; PI_Kinase.
DR   InterPro; IPR001263; PInositide-3_kin_accessory_dom.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   PANTHER; PTHR10048; PTHR10048; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   Pfam; PF00792; PI3K_C2; 1.
DR   Pfam; PF02192; PI3K_p85B; 1.
DR   Pfam; PF00794; PI3K_rbd; 1.
DR   Pfam; PF00613; PI3Ka; 1.
DR   SMART; SM00142; PI3K_C2; 1.
DR   SMART; SM00143; PI3K_p85B; 1.
DR   SMART; SM00144; PI3K_rbd; 1.
DR   SMART; SM00145; PI3Ka; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SUPFAM; SSF48371; SSF48371; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
DR   PROSITE; PS51544; PI3K_ABD; 1.
DR   PROSITE; PS51547; PI3K_C2; 1.
DR   PROSITE; PS51546; PI3K_RBD; 1.
DR   PROSITE; PS51545; PIK_HELICAL; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Autophagy; Cell adhesion; Complete proteome; Cytoplasm;
KW   Endocytosis; Kinase; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transferase.
FT   CHAIN         1   1070       Phosphatidylinositol 4,5-bisphosphate 3-
FT                                kinase catalytic subunit beta isoform.
FT                                /FTId=PRO_0000088787.
FT   DOMAIN       26    115       PI3K-ABD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00877}.
FT   DOMAIN      194    285       PI3K-RBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00879}.
FT   DOMAIN      327    496       C2 PI3K-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00880}.
FT   DOMAIN      524    701       PIK helical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00878}.
FT   DOMAIN      800   1067       PI3K/PI4K. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00269}.
FT   MOTIF       410    418       Nuclear localization signal.
FT   MOD_RES     324    324       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8BTI9}.
FT   MOD_RES    1070   1070       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12502714}.
FT   VARIANT     672    672       Q -> H (in dbSNP:rs2230462).
FT                                /FTId=VAR_050530.
FT   MUTAGEN     342    342       K->N: Enhanced inhibition by PIK3R1
FT                                leading to reduced lipid kinase activity
FT                                and reduced oncogenicity. Does not modify
FT                                regulation by GPCRs.
FT                                {ECO:0000269|PubMed:21030680}.
FT   MUTAGEN     805    805       K->R: Loss of lipid kinase activity. May
FT                                not affect insulin signaling and cell
FT                                proliferation. Partially affects
FT                                oncogene-induced trasformation.
FT                                {ECO:0000269|PubMed:18594509}.
SQ   SEQUENCE   1070 AA;  122762 MW;  81135FE93452C00E CRC64;
     MCFSFIMPPA MADILDIWAV DSQIASDGSI PVDFLLPTGI YIQLEVPREA TISYIKQMLW
     KQVHNYPMFN LLMDIDSYMF ACVNQTAVYE ELEDETRRLC DVRPFLPVLK LVTRSCDPGE
     KLDSKIGVLI GKGLHEFDSL KDPEVNEFRR KMRKFSEEKI LSLVGLSWMD WLKQTYPPEH
     EPSIPENLED KLYGGKLIVA VHFENCQDVF SFQVSPNMNP IKVNELAIQK RLTIHGKEDE
     VSPYDYVLQV SGRVEYVFGD HPLIQFQYIR NCVMNRALPH FILVECCKIK KMYEQEMIAI
     EAAINRNSSN LPLPLPPKKT RIISHVWENN NPFQIVLVKG NKLNTEETVK VHVRAGLFHG
     TELLCKTIVS SEVSGKNDHI WNEPLEFDIN ICDLPRMARL CFAVYAVLDK VKTKKSTKTI
     NPSKYQTIRK AGKVHYPVAW VNTMVFDFKG QLRTGDIILH SWSSFPDELE EMLNPMGTVQ
     TNPYTENATA LHVKFPENKK QPYYYPPFDK IIEKAAEIAS SDSANVSSRG GKKFLPVLKE
     ILDRDPLSQL CENEMDLIWT LRQDCREIFP QSLPKLLLSI KWNKLEDVAQ LQALLQIWPK
     LPPREALELL DFNYPDQYVR EYAVGCLRQM SDEELSQYLL QLVQVLKYEP FLDCALSRFL
     LERALGNRRI GQFLFWHLRS EVHIPAVSVQ FGVILEAYCR GSVGHMKVLS KQVEALNKLK
     TLNSLIKLNA VKLNRAKGKE AMHTCLKQSA YREALSDLQS PLNPCVILSE LYVEKCKYMD
     SKMKPLWLVY NNKVFGEDSV GVIFKNGDDL RQDMLTLQML RLMDLLWKEA GLDLRMLPYG
     CLATGDRSGL IEVVSTSETI ADIQLNSSNV AAAAAFNKDA LLNWLKEYNS GDDLDRAIEE
     FTLSCAGYCV ASYVLGIGDR HSDNIMVKKT GQLFHIDFGH ILGNFKSKFG IKRERVPFIL
     TYDFIHVIQQ GKTGNTEKFG RFRQCCEDAY LILRRHGNLF ITLFALMLTA GLPELTSVKD
     IQYLKDSLAL GKSEEEALKQ FKQKFDEALR ESWTTKVNWM AHTVRKDYRS
//
